Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Pembrolizumab (Keytruda) for classical Hodgkin Lymphoma
(Notification to Implement Issued as of January 22, 2018)

Irinotecan Liposome (Onivyde) for Metastatic Pancreatic Cancer
(Notification to Implement Issued as of January 22, 2018)

Alectinib (Alecensaro) for Non-Small Cell Lung Cancer 
(Open for Input on Submission until January 29, 2018)

Midostaurin (Rydapt) for Acute Myeloid Leukemia 
(Notification to Implement Issued as of January 11, 2018)

Pembrolizumab (Keytruda) for Metastatic Urothelial Carcinoma
(Open for Feedback on Recommendation until January 19, 2018)

Cetuximab (Erbitux) for Left Sided Metastatic Colorectal Carcinoma 
(Pending Submission as of December 13, 2017)


Find a Drug Review